{"id":20986,"date":"2017-07-20T13:00:00","date_gmt":"2017-07-20T19:00:00","guid":{"rendered":"http:\/\/www.salud.carlosslim.org\/english2\/?p=20986"},"modified":"2017-07-20T14:12:31","modified_gmt":"2017-07-20T20:12:31","slug":"scientists-discover-how-the-new-spanish-vaccine-against-tuberculosis-acts-simplifying-clinical-trials","status":"publish","type":"post","link":"http:\/\/www.salud.carlosslim.org\/english2\/scientists-discover-how-the-new-spanish-vaccine-against-tuberculosis-acts-simplifying-clinical-trials\/","title":{"rendered":"Scientists discover how the new Spanish vaccine against tuberculosis acts, simplifying clinical trials"},"content":{"rendered":"

\"\"Spanish researchers have found potential biomarkers of protection against tuberculosis that could accelerate trials of efficacy of a new vaccine<\/strong>. The results, published in Nature Communications<\/em>, reveal that the MTBVAC model could be more beneficial than the current and centennial CGB vaccine against tuberculosis<\/strong>, which causes 1.5 million deaths a year.<\/p>\n

According to the World Health Organization, in the last two years tuberculosis (TB) has overtook AIDS as the leading cause of death due to infectious diseases worldwide<\/strong>. The growing threat of antibiotics resistant and multi-resistant strains makes TB treatment difficult to treat.<\/p>\n

The current vaccine, Calmette-Gu\u00e9rin bacillus (CGB), is an attenuated variant of the TB pathogen and is considered to be effective against severe forms of TB in children, but not against the respiratory forms of the disease in adults<\/strong>, responsible for the disease transmission. Therefore, the development of new vaccines is essential for controlling its spread.<\/p>\n

Researchers at the University of Zaragoza in Spain and Lausanne University Hospital in Switzerland are collaborating on the study of MTBVAC, the first live attenuated tuberculosis vaccine based on Mycobacterium tuberculosis<\/em><\/strong>.<\/p>\n

Now, Nacho Aguil\u00f3, one of the scientists collaborating in the project, has found in mice models treated with MTBVAC the presence of ESAT6 and CFP10 proteins, which are absent in those treated with current CGB vaccine<\/strong>. These proteins are crucial in the immune system stimulation and in the protection mechanism of the vaccine.<\/p>\n

“To date, there were no specific antigens associated with the efficacy of a tuberculosis vaccine. Therefore, with the discovery of these potential biomarkers, efficacy trials of the new vaccine could be accelerated in endemic populations, allowing achieving the goal of eliminating the tuberculosis of the world by the year 2035<\/strong> \u2013according to the objectives of the WHO<\/em>, ” said Aguil\u00f3.<\/p>\n

If MTBVAC finally demonstrates its superior in efficacy at all phases of clinical trials, it could replace the current CGB vaccine and protect millions of children, adolescents and adults from TB<\/strong>. So far, this vaccine has already shown excellent safety and immune response after the first clinical trial in 36 adults in Switzerland. This allowed going one step further and in September 2015 the next phase (phase I-b) began in a TB endemic country, South Africa; in this case with 36 newborns.<\/p>\n

The Aguil\u00f3 study shows that the two major antigens of M. tuberculosis<\/em>, ESAT6 and CFP10, play a key role in the better protection conferred by MTBVAC in mice<\/strong>, in comparison with CGB.  In addition, the study demonstrates that MTBVAC (but not CGB) triggers a specific response against ESAT6 and CFP10 in the volunteers of clinical trials phase I<\/strong> in Lausanne, justifying further exploration of this response as a potential biomarker of protection in upcoming clinical trials of MTBVAC.<\/p>\n

 <\/p>\n

Source: <\/strong>SINC<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Spanish researchers have found potential biomarkers of protection against tuberculosis that could accelerate trials of efficacy of a new vaccine. The results, published in Nature Communications, reveal that the MTBVAC model could be more beneficial than the current and centennial CGB vaccine against tuberculosis, which causes 1.5 million deaths a year. According to the World …<\/p>\n","protected":false},"author":7,"featured_media":20992,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[3],"tags":[11],"class_list":["post-20986","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualidad-en-la-salud","tag-vacunologia","cat-3-id","has_thumb"],"_links":{"self":[{"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/posts\/20986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/comments?post=20986"}],"version-history":[{"count":4,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/posts\/20986\/revisions"}],"predecessor-version":[{"id":20993,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/posts\/20986\/revisions\/20993"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/media\/20992"}],"wp:attachment":[{"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/media?parent=20986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/categories?post=20986"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.salud.carlosslim.org\/english2\/wp-json\/wp\/v2\/tags?post=20986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}